共 124 条
[1]
Romero-Aroca P(2011)Managing diabetic macular edema: the leading cause of diabetes blindness World J Diabetes 2 98-104
[2]
Klein R(1995)The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema Ophthalmology 102 7-16
[3]
Klein BE(2012)Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 35 556-564
[4]
Moss SE(2009)Epidemiology of diabetic retinopathy: expected vs reported prevalence of cases in the French population Diabetes Metab 35 431-438
[5]
Cruickshanks KJ(2016)Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial Ophthalmology 123 1351-1359
[6]
Yau JWY(2016)Intravitreal Aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies Ophthalmology 123 2376-2385
[7]
Rogers SL(2010)Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study Diabetes Care 33 2399-2405
[8]
Kawasaki R(2013)Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE Ophthalmology 120 2013-2022
[9]
Delcourt C(2012)Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 789-801
[10]
Massin P(2015)Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema N Engl J Med 372 1193-1203